e-Newsletter December 2024
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Search results
Our monthly e-Newsletter featuring the latest updates from Retina UK.
Biopharmaceutical company ProQR is conducting a Phase 2/3 clinical trial (Illuminate) to measure the safety and effectiveness of RNA therapy, Sepofarsen which aims to treat Leber's Congenital Amourosis (LCA) 10.
Biotechnology company ProQR has announced encouraging results from its early analysis of the phase 1/2 trial of QR-421a, an innovative approach to treating sight loss caused by mutations in a particular section of the USH2A gene.
Tickle everyone’s taste buds and help raise funds for Retina UK with our Great Bake fundraiser!